Xintela pivots its XSTEM strategy by creating a dedicated subsidiary and securing a SEK 10 million credit facility from Flerie Invest AB to fund operations and target a 2027 market entry.
The company refinines its XSTEM osteoarthritis strategy, establishes a dedicated subsidiary with a new CEO, and secures an interest-free, secured credit facility of up to SEK 10 million from principal shareholder Flerie Invest AB. This provides operational funding without dilution and targets first launch by end of 2027, but it is a strategy outline rather than a hard value-creating event, and the need for shareholder credit signals a funding gap.
Xintela is spinning off its XSTEM osteoarthritis programme into a dedicated subsidiary led by incoming CEO Dr. Stijn Heessen. The company aims for an initial market launch by the end of 2027 while securing a SEK 10 million interest-free credit facility from Flerie Invest AB to support operations through March 2027.
No. It has an interest-free, secured short-term credit facility of up to SEK 10 million from its principal shareholder Flerie Invest AB, available until 30 March 2027, to support ongoing operations while it seeks strategic investors and partners.
The company targets a first launch in selected countries by the end of 2027, based on existing clinical data, where local regulatory frameworks may permit commercialisation.